Achaogen Says First Patient Enrolled In Phase 3 Trial Of Plazomicin

(RTTNews) - Biopharma company Achaogen, Inc. (AKAO) Wednesday said the first patient has been enrolled in its Phase 3 clinical study of plazomicin to treat infections caused by carbapenem-resistant Enterobacteriaceae or CRE. The Phase 3 trial evaluates the superiority, in terms of mortality at 28 days, of a plazomicin-based regimen compared with a colistin-based regimen in CRE patients with bloodstream infections or nosocomial pneumonia. Kenneth Hillan, chief executive of Achaogen said: "We have initiated sites in the U.S. and Europe, and will further expand to sites in other important geographic regions in the coming months."